Restart Life Sciences Reports Record-Breaking June Revenue for Holy Crap Foods as Amazon Canada Sales Surge YoY

About this update from Restart Life Sciences Corp.

Vancouver, British Columbia--(Newsfile Corp. - July 2, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to report its preliminary, unaudited financial results for the month of June 2026 regarding its wholly owned subsidiary, Holy Crap Foods Inc., alongside an update on internal operational infrastructure and market expansion initiatives. Following the acquisition of Holy Crap Foods Inc. on February 27, 2026, the Company has focused on integrating operations, improving channel efficiencies, and expanding distribution networks. June 2026 Financial Results The Company's core revenue remains supported by its Canadian retail distribution network, which encompasses over 800 retail locations, alongside direct and 2-step commercial distribution streams. Operational Infrastructure Updates Management continues to fine-tune multiple facets of the business to optimize efficiency and support long-term administrative and commercial scalability. Current internal initiatives include: Product Development and Market Expansion Outlook The Company will be providing updates shortly regarding its upcoming milestones, which include: Management expects that the regional and international expansion initiatives currently being initiated will enhance the Company's current operational and financial projections. These expansions are designed to launch utilizing product marketing models similar to the initiatives successfully deployed in its baseline markets. "The performance in June reflects the ongoing integration of Holy Crap Foods into our operational framework," said Steve Loutskou, Chief Executive Officer of Restart Life Sciences. "Beyond top-line metrics, our team is systematically fine-tuning our foundational business systems. The implementation of our new CRM platform, the refinement of our digital assets, and our upcoming product pipelines are key components of this process. We look forward to providing updates shortly on our expansion strategies, which we expect will enhance our current projections as we introduce our established marketing models into new markets."

View stock analysis, news, and events for Restart Life Sciences Corp.